GlassScriptPhysician profile
Harry R Lively
NPI 1922154863
$8,150.57
in general payments reported to CMS, 2019-2025
28 companies · $4,216 in 2025
The $4,216 reported for 2025 was more than what 91% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,552 · 2020: $175 · 2021: $51.83 · 2022: $469 · 2023: $511 · 2024: $1,174 · 2025: $4,216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,851 · Travel and Lodging: $2,051.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,850.68 |
| Travel and Lodging | $2,051.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Siemens Medical Solutions USA, INC. | $2,119.37 | 2024-2025 | Acuson Origin Diagnostic Ultrasound System, Acuson Sequoia Diagnostic Ultrasound System |
| Boston Scientific Corporation | $1,625.97 | 2019-2025 | Lux-Dx Insertable Cardiac Monitor, Avvigo Guidance System, Vigilant X4 Crt-D |
| Novartis Pharmaceuticals Corporation | $518.64 | 2019-2024 | |
| Medtronic, INC. | $437.41 | 2025 | Micra, Aurora Ev-Icd Mri Surescan |
| Abiomed | $433.47 | 2019-2025 | Impella |
| Artivion, INC. | $402.00 | 2019 | |
| Amgen INC. | $389.35 | 2019-2024 | Repatha |
| Lantheus Medical Imaging, INC. | $341.41 | 2019-2023 | Definity |
| Cathworks, INC. | $219.77 | 2022 | |
| Abbott Laboratories | $211.59 | 2019-2023 | Coroflow |
| Cvrx, INC. | $207.19 | 2024-2025 | Barostim Neo System |
| Novo Nordisk INC | $152.92 | 2023-2025 | Wegovy |
| Bard Peripheral Vascular, INC. | $150.09 | 2024 | Venovo |
| Shockwave Medical, INC | $142.13 | 2025 | |
| Edwards Lifesciences Corporation | $138.46 | 2019-2024 | Sapien 3 Ultra Resilia |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $129.13 | 2019-2024 | Xarelto |
| Actelion Pharmaceuticals US, INC. | $121.32 | 2024 | Uptravi, Opsumit |
| Teva Pharmaceuticals USA, INC. | $99.91 | 2025 | Austedo Xr |
| Bracco Diagnostics INC. | $88.67 | 2025 | |
| Chiesi USA, INC. | $40.96 | 2021-2023 | Cleviprex, Kengreal |
| Inari Medical, INC. | $40.12 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Pfizer INC. | $28.87 | 2025 | |
| Alnylam Pharmaceuticals INC. | $26.90 | 2025 | Amvuttra |
| Esperion Therapeutics, INC. | $20.13 | 2024 | Nexletol |
| Merck Sharp & Dohme LLC | $18.95 | 2024 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $18.84 | 2024 | Farxiga |
| Lilly USA, LLC | $15.75 | 2025 | Zepbound |
| Masimo Corporation | $11.25 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harry Lively listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.